



HAL
open science

Severe and refractory anaphylaxis in paediatric intensive care unit.

Guillaume Pouessel, Capucine Trochu, Flore Chagnon, Rémy Diesnis,
Stephane Leteurtre, Antoine Deschildre

► **To cite this version:**

Guillaume Pouessel, Capucine Trochu, Flore Chagnon, Rémy Diesnis, Stephane Leteurtre, et al.. Severe and refractory anaphylaxis in paediatric intensive care unit.. Allergy, 2023, Allergy, 10.1111/all.15712 . hal-04524563

HAL Id: hal-04524563

<https://hal.univ-lille.fr/hal-04524563v1>

Submitted on 23 Apr 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

DOI: 10.1111/all.15712

Severe and refractory anaphylaxis in pediatric intensive care unit

To the Editor,

Data regarding severe anaphylaxis (SA) are limited. A new entity called refractory anaphylaxis (RA) has emerged in the literature, although there are subtle differences between the three definitions proposed (Table S1).^{1–3} A 21-member panel of experts in United States (US) has proposed RA to be defined as reactions treated with ≥ 3 appropriate doses of adrenaline (or initiation of an intravenous [IV] adrenaline infusion) in addition to symptom directed medical management (Table S1).³ RA appears to be rare, around 2% of anaphylaxis.⁴

We previously reported a cohort of 166 children (<18 years) admitted to pediatric intensive care units (PICU) for anaphylaxis (2003–2013).⁵ In the current study, we identified which of these children met the US definition for RA, and how they compared with those who were treated with ≥ 2 adrenaline doses and additional therapy which we defined as SA, and determined risk factors for either SA or RA (Methods in Appendix S1).

Data were missing for 32 children, and so the analysis cohort consisted in children, of whom 70 (51%) had SA and 52 (38%) had RA (Table 1). Drugs were the most common elicitor for both SA and RA, followed by foods. SA and RA occurred mainly in hospital (67% and 71%, respectively) and in operating theatre (36% and 40%), or during an oral food challenge (OFC) (13% and 12%).

The treatment and clinical symptoms according to organ system involvement from the first medical rescue to the first 24 h in PICU are described by time periods in children with either SA or RA (Figure 1 and Figure S1). Rapid clinical recovery has been reported with a normal examination within the first 6 h from PICU admission in the majority of children. However, three fatal anaphylaxis have been recorded, all related to foods and one following an OFC.

Children with RA were less likely to have a history of asthma ($p = .04$) or prior anaphylaxis ($p = .05$), although these were not

significant at multivariate logistic analysis, possibly because these are less common in children with drug-induced anaphylaxis. RA-cases were more likely to receive IV bolus adrenaline ($p < .001$), IV adrenaline infusion ($p < .001$), and mechanical ventilation ($p = .015$) during the first 24 h in PICU (Table S2). With regards to adrenaline route according to elicitors and places of reaction, a majority of children treated with IV adrenaline had a drug-related anaphylaxis (58%) mostly in a perioperative setting (76%) (Tables S3 and S4). IM adrenaline was mostly used for food-related anaphylaxis (39%) and rarely in a perioperative setting (7%). In a multivariate logistic analysis, hypotonia at first medical rescue was the only factor predicting both SA (OR: 4.05; 95% CI: 1.24–13.28; $p = .02$) and RA (OR: 5.73; 95% CI: 1.62–20.26; $p = .01$) (Table S5).

Our data are the first to describe in details a series of children admitted to PICU for SA and even RA regarding their main characteristics, the time course of clinical manifestations and treatment. Whereas food is the main elicitor of anaphylaxis in children, drug was here the most common elicitor of both SA and RA, mainly in a perioperative setting, which is also reported by the European Anaphylaxis Registry.² However, foods are common in SA. SA occurred during an OFC in 9/51 (18%) food-related anaphylaxis cases and RA in 6/51 (12%), which reinforce the need to follow a rigorous procedure for OFC implementation with a team trained to manage SA. In RA, the use of IV adrenaline infusion and fluid therapy was insufficient in contradiction with current guidelines.¹ Our data highlight how difficult it is to identify the patients the most at risk of SA or even RA, as previously reported.⁶ However, we found that hypotonia at first medical rescue was a critical characteristic independently associated with either SA or RA.

A worldwide consensus on RA definition is now urgently required as well as registries from childhood to elderly to better characterize risk factors and specificities according to age or elicitors.

The French Group for Paediatric Intensive Care and Emergencies members are in Appendix 1.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2023 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

TABLE 1 Characteristics and elicitors of 70 children admitted to pediatric intensive care units with severe anaphylaxis (treated with ≥ 2 adrenaline doses and additional therapy) including 52 children with refractory anaphylaxis and comparison to children with non-severe anaphylaxis ($n = 68$) and non-refractory anaphylaxis ($n = 86$).

	Severe anaphylaxis N = 70 (%)	Non severe anaphylaxis N = 68 (%)	p	Refractory anaphylaxis N = 52 (%)	Non refractory anaphylaxis N = 86 (%)	p
Male gender, n (%)	41 (59)	34 (50)	.40	26 (50)	49 (57)	.53
Mean age, year (SD)	8.9 (5.3)	7.9 (5.6)	.28	8.95 (5.58)	8.06 (5.43)	.36
Median age, year (IQR)	10.2 (4.4–13.2)	7.3 (2.8–13)	.28	10.9 (4.12–13.35)	7.9 (3.12–12.97)	.38
Age <6 years	24 (34)	30 (44)	.24	19 (37)	35 (41)	.15
6–11 years	17 (24)	19 (28)		10 (19)	26 (30)	
Age >11 years	29 (41)	19 (28)		23 (44)	25 (29)	
Medical history						
Asthma	21 (30)	24 (35)	.63	11 (21)	34 (40)	.04
Food allergy	22 (33)	23 (34)	.76	14 (27)	31 (37)	.29
Prior anaphylaxis	6 (9)	5 (7)	1	1 (2)	10 (15)	.047
ICU admission for anaphylaxis	3 (4)	3 (4)	1	1 (2)	5 (6)	.41
Elicitors						
Foods	25 (36)	26 (37)		14 (27)	37 (43)	
Peanut	8 (11)	8 (12)		5 (10)	11 (13)	
Cow's milk	6 (9)	7 (10)		4 (8)	9 (10)	
Tree nuts	6 (9)	4 (6)		3 (6)	7 (8)	
Other foods	5 (7)	7 (10)		2 (4)	10 (12)	
Drugs	35 (50)	35 (51)		28 (54)	42 (49)	
Antibiotics	8 (11)	10 (15)		5 (10)	13 (15)	
Contrast media	4 (6)	2 (3)		3 (6)	3 (3)	
Cancer chemotherapy	3 (4)	4 (6)		2 (4)	5 (6)	
NMBA	3 (4)	1 (6)		3 (6)	1 (1)	
Other drugs	17 (24)	18 (26)		15 (29)	20 (23)	
Other elicitors	10 (14)	7 (10)		10 (19)	7 (8)	
Insect venom	2 (3)	2 (3)		2 (4)	2 (2)	
Latex	2 (3)	1 (1)		2 (4)	1 (1)	
Foods vs drugs vs others			.77			.058
Place of the reaction						
In hospital	47 (67)	42 (62)	.63	37 (71)	52 (60)	.28
Operating theatre	25 (36)	17 (25)	.40	21 (40)	21 (24)	.31
OFC	9 (13)	8 (12)		6 (12)	11 (13)	

Abbreviations: ICU, intensive care unit; IQR, interquartile range; NC, non calculated; NMBA, neuromuscular blocking agent; OFC, oral food challenge; SD, standard deviation.




FIGURE 1 Therapy administered in 70 children with severe anaphylaxis (bar graph) including 52 with refractory anaphylaxis (red points) from first medical rescue to the first 24 h in pediatric intensive care admission (ICU) (by time periods at first medical rescue, at admission to pediatric ICU -H0-, from H0 to 6 h -H6-, from H6 to H12, from H12 to H24). IM, intramuscular; IV, intravenous.

ACKNOWLEDGMENT

We acknowledge the members of the French Group for Paediatric Intensive Care and Emergencies for their contribution to this survey.

CONFLICT OF INTEREST STATEMENT

GP has provided consultation and speaker services for Aimmune Therapeutics/Nestlé, Bausch and Lomb, Stallergenes, Novartis, ALK-Abello, Bioprojet; serves as a medical consultant/advisor for Bioprojet and AI Therapeutics/Nestlé. AD reports personal fees from Novartis, ALK, GSK, Sanofi, Regeneron, Aimmune Therapeutics, DBV Technologies, Nestlé, Stallergenes Greer, DBV Technologies, Nutricia. Grant from Fondation du Souffle, Conseil Régional Hauts-de-France Research Program 2014–2018, outside the submitted work. The other authors declare to have no conflict of interest. The other co-authors declare no conflict of interest in relation with this work.

Guillaume Pouessel^{1,2}
 Capucine Trochu¹
 Flore Chagnon³
 Rémy Diesnis⁴
 Stéphane Leteurtre⁵
 Antoine Deschildre²

the French Group for Paediatric Intensive Care and Emergencies (FGPICE)

¹Department of Paediatrics, Children's Hospital, Roubaix, France

²Paediatric Pulmonology and Allergy Department, Hôpital Jeanne de Flandre, CHU Lille, Lille, France

³Department of Paediatrics, Children's Hospital, Valenciennes, France

⁴Clinical Research Unit, Department of Biostatistics, Roubaix Hospital, Roubaix, France

⁵Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des, pratiques médicales, F-59000, Lille, France

Correspondence

Guillaume Pouessel, Department of Paediatrics, CH Roubaix, Boulevard Lacordaire, F-59056 Roubaix, France.
 Email: guillaume.pouessel@ch-roubaix.fr; guillaume.pouessel@ch-roubaix.fr; guillaume.pouessel@gmail.com

REFERENCES

- Sargant N, Dodd A, Hughes A, Whyte AF, Soar J, Turner PJ. Refractory anaphylaxis: treatment algorithm. *Allergy*. 2021;76(5):1595–1597. doi:10.1111/all.14780
- Francuzik W, Dölle-Bierke S, Knop M, et al. Refractory anaphylaxis: data from the European anaphylaxis registry. *Front Immunol*. 2019;10:2482. doi:10.3389/fimmu.2019.02482
- Dribin TE, Sampson HA, Camargo CA Jr, et al. Persistent, refractory, and biphasic anaphylaxis: a multidisciplinary Delphi study. *J Allergy Clin Immunol*. 2020;146(5):1089–1096.

- Patel N, Chong KW, Yip AYG, et al. Use of multiple epinephrine doses in anaphylaxis: a systematic review and meta-analysis. *J Allergy Clin Immunol.* 2021;148(5):1307-1315.
- Pouessel G, Chagnon F, Trochu C, et al. French Group for Pediatric Intensive Care and Emergencies (GFRUP). Anaphylaxis admissions to pediatric intensive care units in France. *Allergy.* 2018;73:1902-1905.
- Turner PJ, Arasi S, Ballmer-Weber B, et al. Risk factors for severe reactions in food allergy: rapid evidence review with meta-analysis. *Allergy.* 2022;77(9):2634-2652. doi:10.1111/all.15318

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

APPENDIX 1

Collaborators of the French Group for Pediatric Intensive Care and Emergencies

Pierre Tourneux (MD, PhD, Amiens), Gerald Boussicault (MD, Angers), Gérard Thiriez (MD, PhD, Besançon), Olivier Brissaud

(MD, PhD, Bordeaux), Armelle Garenne (MD, Brest), Mickael Jokic (MD, Caen), Isabelle Petit (MD, Clermont-Ferrand), Denis Semama (MD, Dijon), Jean Bergounioux (MD, PhD, Garches), Thierry Debillon (MD, PhD, Grenoble), Isabelle Wroblewski (MD, Grenoble), Aimée Dorkenoo (MD, Lille), Eric Mallet (MD, Limoges), Etienne Javouhey (MD, PhD, Lyon), Blandine Vanel (MD, Lyon), Renaud Vialet (MD, Marseille- Hopital Nord), Fabrice Michel (MD, PhD, Marseille -Hôpital Timone), Gilles Cambonie (MD, PhD, Montpellier), Christophe Milesi (MD, Montpellier), Noël Boussard (MD, Nancy), Nicolas Joram (MD, Nantes), Didier Dupont (MD, PhD, Nice), Pierre Tissières (MD, PhD, Paris-Bicêtre), Stéphane Dager (MD, PhD, Paris-Robert Debré), Sylvain Renolleau (MD, PhD, Paris-Necker), Pierre-Louis Léger (MD, PhD, Paris-Trousseau), Thierry Mansir (MD, Pau), Jean-Pascal Saulnier (MD, Poitiers), Nathalie Bednarek (MD, PhD, Reims), Olivier Tirel (MD, Rennes), Thierry Blanc (MD, Rouen), Hugues Patural (MD, PhD, Saint-Etienne), Dominique Astruc (MD, Strasbourg), Marie-Odile Marcoux (MD, Toulouse), Romain Amadiou (MD, Toulouse), Julie Chantreuil (MD, Tours).

DOI: 10.1111/all.15713

Microbes, antibodies, and breastfeeding as the trans-generational axis of microbiota maturation

To the Editor,

It is well established that in a newborn, the microbiota and immunity engage in constant interactions that can set an individual on a trajectory toward health or disease.

Apart from vaginal delivery, breastfeeding is a powerful way mothers use to influence the health of their offspring. The importance of breast milk in preventing infant mortality has been known for more than a century¹ and has been attributed, at least in part, to the immune exclusion of pathogenic bacteria by secretory immunoglobulin A (sIgA).² One such example includes the binding of maternal sIgA to *Enterobacteriaceae*, which prevents the development of necrotizing enterocolitis in preterm infants.³

The popularization of next-generation sequencing (NGS) in the first decade of the 21st century has started a revolution in unraveling the impact of commensal microbes on human health. Given a tight association between the microbiota and IgA, new roles for breast-milk sIgA have started to be proposed. By combining advances in flow cytometry and NGS, Sterlin et al., showed that milk sIgA binds bacteria, which are associated with the infant's health and thrive early in life, for example, *Bifidobacterium longum*.⁴ This observation was not in line with the immune exclusion function of sIgA (although the exact consequences of antibody coating, in this case, were not unraveled). Also, details behind *B. longum* – sIgA interactions have

not been fully elucidated but might involve the recognition of microbial glycans by the variable regions of sIgA.⁴ Understanding the functional impact of sIgA – *B. longum* interactions is particularly important in light of the health benefits this commensal brings to the host. The examples include dampening intestinal inflammation (in a process involving the induction of a negative regulator of Th2 and Th17 cell function, galectin-1, by *B. longum*-derived indole-3-lactic acid⁵), and the protection against enteropathogenic infection (in a process involving bacterial production of acetate⁶). Earlier studies have also indicated the roles of breastmilk sIgA that extend beyond the immune exclusion. For example, Rogier et al., noted that, in addition to preventing the translocation of aerobic bacteria from the gut to the mesenteric lymph nodes, sIgA-containing milk imprinted broad and long-lasting changes in the microbiota composition of the offspring.⁷

It is interesting to note that antigen specificity of sIgA in breast milk may be influenced by the mother's gut microbiota. For example, Usami et al., indicated the presence of *Bacteroides acidifantis*-specific IgA⁺ plasma cells in lactating mammary glands, which were of Peyer's patches origin.⁸ This observation opens up a possibility that sIgA imprints certain microbial changes in the neonatal intestinal tract based on the mother's gut microbiota. Identifying further examples, and unraveling the functional impact of antibody